# Arcus Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arcus-biosciences

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.arcusbio.com
- Total disclosed funding: $227M
- Latest round: Series C (Nov 3, 2017)
- Investors on record: 17

## About

Founded in 2015 and based in California, US, Arcus Biosciences, Inc. is a biotechnology company that develops immunotherapies for the treatment of cancer. In January 2024, Gilead Sciences, Inc. acquired Arcus Biosciences, Inc. for USD 320 million in common stock at USD 21.00 per share. The firm as of July 2024, has offices in Hayward and Brisbane, California, and is led by its CEO, Terry Rosen.

Arcus Biosciences has a robust pipeline of clinical candidates targeting various biological pathways critical to cancer progression. These include Anti-TIGIT (domvanalimab), Adenosine Axis (etrumadenant, quemliclustat), Anti-PD-1 (zimberelimab), HIF-2? Inhibitor (casdatifan), Anti-CD39 (AB598), and AXL Inhibitor (AB801). These candidates are designed to address high unmet medical needs across multiple cancer types, such as lung, gastrointestinal, kidney, pancreatic, and colorectal cancers. The company's development approach is moving from program initiation to investigational new drug (IND) filing in record time, and progressing rapidly through clinical phases.

The January 2024 acquisition will allow Arcus to concentrate on developing several pipeline assets, including both Gilead-optioned and non-optioned initiatives, while also assisting Gilead Sciences, Inc. in expediting the domvanalimab program.

## Funding rounds

- Series C, Nov 3, 2017, $107M — Aisling Capital, The Column Group, Invus [DUP], Wellington Management, GV, Leerink Partners, Hillhouse Investment, Foresite Capital, Decheng Capital, BVF Partners, EcoR1 Capital, Bristol-Myers Squibb Company, Taiho Ventures, Droia Ventures
- Series B, Aug 15, 2016, $70M — The Column Group, Invus [DUP], GV, Celgene, Stanford University, Foresite Capital, Novartis, Taiho Ventures, Droia Ventures
- Series A, May 1, 2015, $50M — The Column Group, Celgene, Foresite Capital, Novartis

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- Celgene — Series A, Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B, Series C
- Novartis — Series A, Series B
- Invus [DUP] — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Stanford University — Series B
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series B, Series C
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series B, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Leerink Partners — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Bristol-Myers Squibb Company — Series C